Literature DB >> 27262366

Clinical, biopsy, and mass spectrometry characteristics of renal apolipoprotein A-IV amyloidosis.

Surendra Dasari1, Md Shahrier Amin2, Paul J Kurtin2, Julie A Vrana2, Jason D Theis2, Karen L Grogg2, Mariam P Alexander2, Samih H Nasr2, Fernando C Fervenza3, Nelson Leung3, Sanjeev Sethi4.   

Abstract

Apolipoprotein A-IV associated amyloidosis (AApoAIV amyloidosis) is a rare cause of amyloidosis with only a single reported case. Here we describe the clinical, biopsy, and mass spectrometry characteristics of 11 cases of renal AApoAIV amyloidosis encompassing 9 men and 2 women with a mean age at diagnosis of 63.5 years. Progressive chronic kidney disease (mean serum creatinine 2.9 mg/dl) was the most common cause for biopsy with proteinuria absent or minimal in all except one. Hematological and serological evaluation was negative in 9 patients, while 2 had a monoclonal gammopathy. The renal biopsy findings were striking and showed large amounts of eosinophilic Congo-red positive amyloid deposits restricted to the renal medulla with sparing of the renal cortex. In 6 cases, peritubular amyloid was noted in addition to the interstitial involvement. Immunofluorescence studies were negative for immunoglobulins. Electron microscopy showed nonbranching fibrils measuring 7 to 10 nm in diameter. Laser microdissection of the amyloid deposits followed by mass spectrometry showed large spectra number (a semiquantitative measure of abundance) for AApoAIV protein ranging from 49 to 169 (average 85), serum amyloid protein (average 19), and apolipoprotein E (average 48). Importantly, no peptides were detected for any other forms of known amyloidogenic precursor proteins. Thus, renal AApoAIV amyloidosis typically presents with progressive chronic kidney disease and histologically exhibits extensive medullary involvement with sparing of the cortex. The diagnosis is best established by mass spectrometry. Hence, a high degree of suspicion and examination of the renal medulla is required to make the diagnosis.
Copyright © 2016 International Society of Nephrology. Published by Elsevier Inc. All rights reserved.

Entities:  

Keywords:  amyloid; apolipoprotein A-IV; laser microdissection; mass spectrometry; medulla

Mesh:

Substances:

Year:  2016        PMID: 27262366     DOI: 10.1016/j.kint.2016.04.003

Source DB:  PubMed          Journal:  Kidney Int        ISSN: 0085-2538            Impact factor:   10.612


  13 in total

Review 1.  Pathology and diagnosis of renal non-AL amyloidosis.

Authors:  Sanjeev Sethi; Jason D Theis
Journal:  J Nephrol       Date:  2017-08-21       Impact factor: 3.902

2.  Disrupting the DREAM transcriptional repressor complex induces apolipoprotein overexpression and systemic amyloidosis in mice.

Authors:  Pirunthan Perampalam; Haider M Hassan; Grace E Lilly; Daniel T Passos; Joseph Torchia; Patti K Kiser; Andrea Bozovic; Vathany Kulasingam; Frederick A Dick
Journal:  J Clin Invest       Date:  2021-02-15       Impact factor: 14.808

3.  A systemic apolipoprotein A-IV-associated amyloidosis confirmed by proteome analysis.

Authors:  Taro Murakami; Akira Takasawa; Asako Moriki; Yusuke Igaki; Hiroshi Ikeda; Kazuyuki Murase; Kohichi Takada; Kazufumi Magara; Tomoyuki Aoyama; Yusuke Ono; Daisuke Kyuno; Kumi Takasawa; Masaki Murata; Makoto Osanai
Journal:  Virchows Arch       Date:  2021-03-10       Impact factor: 4.064

4.  Optimal conditions and the advantages of using laser microdissection and liquid chromatography tandem mass spectrometry for diagnosing renal amyloidosis.

Authors:  Michiko Aoki; Dedong Kang; Akira Katayama; Naomi Kuwahara; Shinya Nagasaka; Yoko Endo; Mika Terasaki; Shinobu Kunugi; Yasuhiro Terasaki; Akira Shimizu
Journal:  Clin Exp Nephrol       Date:  2018-01-25       Impact factor: 2.801

5.  The Clinical Impact of Proteomics in Amyloid Typing.

Authors:  Michelle M Hill; Surendra Dasari; Peter Mollee; Giampaolo Merlini; Catherine E Costello; Bouke P C Hazenberg; Martha Grogan; Angela Dispenzieri; Morie A Gertz; Taxiarchis Kourelis; Ellen D McPhail
Journal:  Mayo Clin Proc       Date:  2021-04-09       Impact factor: 11.104

6.  Hereditary Renal Amyloidosis Associated With a Novel Apolipoprotein A-II Variant.

Authors:  Tatiana Prokaeva; Harun Akar; Brian Spencer; Andrea Havasi; Haili Cui; Carl J O'Hara; Olga Gursky; John Leszyk; Martin Steffen; Sabrina Browning; Allison Rosenberg; Lawreen H Connors
Journal:  Kidney Int Rep       Date:  2017-07-29

7.  Increasing the accuracy of proteomic typing by decellularisation of amyloid tissue biopsies.

Authors:  P Patrizia Mangione; Giuseppe Mazza; Janet A Gilbertson; Nigel B Rendell; Diana Canetti; Sofia Giorgetti; Luca Frenguelli; Marco Curti; Tamer Rezk; Sara Raimondi; Mark B Pepys; Philip N Hawkins; Julian D Gillmore; Graham W Taylor; Massimo Pinzani; Vittorio Bellotti
Journal:  J Proteomics       Date:  2017-06-21       Impact factor: 4.044

8.  Apolipoprotein CII Amyloidosis Associated With p.Lys41Thr Mutation.

Authors:  Sanjeev Sethi; Surendra Dasari; Emmanuelle Plaisier; Pierre Ronco; Samih H Nasr; Isabelle Brocheriou; Jason D Theis; Julie A Vrana; Michael T Zimmermann; Patrick S Quint; Ellen D McPhail; Paul J Kurtin
Journal:  Kidney Int Rep       Date:  2018-04-22

9.  Characterization of the Cerebrospinal Fluid Proteome in Patients with Fragile X-Associated Tremor/Ataxia Syndrome.

Authors:  Diana A Abbasi; Thu T A Nguyen; Deborah A Hall; Erin Robertson-Dick; Elizabeth Berry-Kravis; Stephanie M Cologna
Journal:  Cerebellum       Date:  2021-05-27       Impact factor: 3.847

10.  Accelerated pre-senile systemic amyloidosis in PACAP knockout mice - a protective role of PACAP in age-related degenerative processes.

Authors:  Dora Reglodi; Adel Jungling; Rémi Longuespée; Joerg Kriegsmann; Rita Casadonte; Mark Kriegsmann; Tamas Juhasz; Sebastian Bardosi; Andrea Tamas; Balazs Daniel Fulop; Krisztina Kovacs; Zsuzsanna Nagy; Jason Sparks; Attila Miseta; Gabriel Mazzucchelli; Hitoshi Hashimoto; Attila Bardosi
Journal:  J Pathol       Date:  2018-07-04       Impact factor: 7.996

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.